Vn96* Peptide, a novel tool for convenient and efficient enrichment of urinary eMVs containing informative prostate cancer protein and mRNA biomarkers

Details: Conference Paper

Early detection of prostate cancer (PCa) currently relies on serum PSA and digital rectal examination (DRE), both of which lack diagnostic specificity and prognostic value. Hence, there is a great demand for new and better PCa biomarkers. Urinary extracellular microvesicles (eMVs) have valuable potential as a novel, noninvasive
and enriched source of biomarkers. Conventional means of eMV isolation involve time-consuming ultracentrifugation (UCF) or expensive commercial methods. Our group has developed a fast, simple and cost-effective method for enrichment of eMVs from urine using a peptide (Vn96) with affinity for heat shock proteins.
PDF

Excipio Technologies Inc.

35 Providence Street
Moncton, New Brunswick
E1C 8X3
Canada
info@excipio.ca

ME^TM Kit product information:
sales@newenglandpeptide.com

Business Development Contact:
Remi Richard
Business Development Agent
remi.richard@canceratl.ca
Phone : +1 506 869 2048
Fax : +1 506 862 7571

Unlock the diagnostic potential of exosomes

Increase the specificity and sensitivity of your biofluid-based molecular diagnostic assays with Vn96. The Vn96 platform technology can give you access to improved clinical diagnostics directly on site or at point-of-care with faster, more specific and efficient exosome isolation. All while using your existing infrastructure, minimizing your isolation time to less than an hour and eliminating the need for ultracentrifugation or expensive antibodies and filtration methods.

Publications